Device Validation of Augmented-Reality ICG Fluorescence Imaging for Sentinel Lymph Node Detection in Breast Cancer

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorSs. Cyril and Methodius University of Skopje

About this trial

This study evaluates how accurately augmented-reality goggles with indocyanine green (ICG) near-infrared fluorescence can identify sentinel (first-draining) lymph nodes during breast cancer surgery. The goggles and ICG signal are used to mark candidate sentinel nodes, and an additional observer may record near-infrared images during the operation for device-performance assessment. These imaging findings do not change the surgical procedure. The candidate nodes and all removed tissue are examined by histopathology, which serves as the reference standard. Two hundred patients undergoing breast cancer surgery will take part. The study measures how well the goggle-based imaging detects nodes that contain cancer, compared with final pathology.

Eligibility criteria

Qualifiers

Histologically proven breast cancer

Age 18 years or older

Undergoing breast cancer surgery with sentinel lymph node evaluation and/or axillary lymph node dissection

Provides written informed consent

Disqualifiers

Pregnancy

Neoadjuvant chemotherapy

Prior breast surgery

Iodine or seafood allergy

Trial design

Treatments tested in this trial

  • AR-ICG near-infrared fluorescence imaging

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Ss. Cyril and Methodius University of Skopje

Lead sponsor

University of Illinois at Urbana-Champaign

Collaborator